


Applicants: Guy Benchley et al.
 Application No.: 10/809,946

AMENDMENTS TO THE CLAIMS

Please replace all prior versions and listings of claims with the amended claims as follows:

1. (Currently amended) A compound of formula (I):

[[I]]




I

or a pharmaceutically acceptable salt thereof, wherein:

R^1 and R^2 are each independently R, halogen, CN, NO_2 , or TR, ~~or R^1 and R^2 taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5- or 6-membered ring having 0-3 heteroatoms independently selected from N, O, or S;~~

T is an optionally substituted C_1 - C_4 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by O, N(R), C(O), S, SO, or SO_2 ;

Ar^1 is



wherein each occurrence of QR^5 is, independently, CH_2 halogen, halogen, CH_2 CN, CN, CH_2CO_2R' , CO_2R' , CH_2COR' , COR' , R' , CH_2NO_2 , NO_2 , CH_2OR' , OR' , CH_2SR' , SR' , haloalkyl, $CH_2SO_2N(R')_2$, $SO_2N(R')_2$, $CH_2N(R')_2$, $N(R')_2$, $NHCOR'$, CH_2NHCOR' , $CH_2PO(OR')_2$, $PO(OR')_2$

~~an optionally substituted ring selected from: an aryl group selected from a 5-6 membered monocyclic or an 8-10 membered bicyclic ring having 0-5 heteroatoms~~

Applicants: Guy Benchley et al.
 Application No.: 10/809,946

~~independently selected from nitrogen, oxygen, or sulfur; a 3-8 membered saturated or partially unsaturated ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8-10 membered saturated or partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein Ar¹ is optionally substituted at one or more carbon atoms with 0-5 occurrences of -Q-R⁵, and at one or more substitutable nitrogen atoms with -R⁶ and each occurrence of R⁶ is independently R', -COR', -CO₂(C₁₋₆ aliphatic), -CON(R')₂, -SO₂N(R')₂, or -SO₂R';~~

R³ and R⁴ are each independently Z-R⁷, or R³ and R⁴ are taken together to form an optionally substituted saturated, partially unsaturated, or fully unsaturated 3-8 membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur wherein said ring is optionally substituted with 0-5 independent occurrences of Y-R⁸;

each occurrence of Q, Z, and Y is independently a bond or an optionally substituted C₁-C₆ alkylidene chain wherein up to two non-adjacent methylene units of Q and up to three non-adjacent methylene units of Z are optionally replaced by CO, CO₂, COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, NRCO₂, NRCONR, SO, SO₂, NRSO₂, SO₂NR, NRSO₂NR, O, S, or NR;

each occurrence of R⁵, R⁷ and R⁸ is independently R', halogen, NO₂, CN, OR', SR', N(R')₂, NR'C(O)R', NR'C(O)N(R')₂, NR'CO₂R', C(O)R', CO₂R', OC(O)R', C(O)N(R')₂, OC(O)N(R')₂, SOR', SO₂R', SO₂N(R')₂, NR'SO₂R', NR'SO₂N(R')₂, PO(OR')₂, C(O)C(O)R', or C(O)CH₂C(O)R'; and

each occurrence of R is independently hydrogen or an optionally substituted C₁₋₆ aliphatic group; and each occurrence of R' is independently hydrogen or an optionally substituted group selected from C₁₋₈ aliphatic, C₆₋₁₀ aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 3-10 ring atoms, or wherein two occurrences of R taken together, R and R' taken together, or two occurrences of R' taken together, form an optionally substituted saturated,

Applicants: Guy Benchley et al.
 Application No.: 10/809,946

partially unsaturated, or fully unsaturated 3-8 membered ring having 0-3
 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
 provided that [[:]]

- [[i)]] R^3 and R^4 are not simultaneously hydrogen; and
 ii) — when R^3 and R^4 are both methyl, or R^3 is methyl and R^4 is $(CH_2)_2OH$,
 then Ar^1 is not 3,4,5-trimethoxyphenyl.

2-6. (Canceled)

7. (Currently amended) The compound of claim 1, wherein both
~~occurrences of $Q-R^5$ are methyl Q is independently a bond or is an optionally~~
~~substituted C_1-C_4 alkylidene chain wherein up to two non-adjacent methylene units of~~
 ~~Q are optionally replaced by CO , CO_2 , $CONR$, $OCONR$, $NRCO$, $NRCO_2$, $NRSO_2$,~~
 ~~SO_2NR , O , S , or NR ; and each occurrence of R^5 is independently selected from R' ,~~
~~halogen, NO_2 , CN , OR' , SR' , $N(R')_2$, $NR'C(O)R'$, $NR'C(O)N(R')_2$, $NR'CO_2R'$,~~
 ~~$C(O)R'$, CO_2R' , $OC(O)R'$, $C(O)N(R')_2$, $OC(O)N(R')_2$, SOR' , SO_2R' , $SO_2N(R')_2$,~~
 ~~$NR'SO_2R'$, $NR'SO_2N(R')_2$, $PO(OR')_2$, $C(O)C(O)R'$, or $C(O)CH_2C(O)R'$, and x is 0,~~
~~1, 2, or 3.~~

8. (Currently amended) The compound of claim 1, wherein at least one
~~occurrence of $Q-R^5$ is CF_3 $Q-R^5$ substituents on Ar^1 are CH_2 halogen, halogen,~~
 ~~CH_2CN , CN , CH_2CO_2R' , CO_2R' , CH_2COR' , COR' , R' , CH_2NO_2 , NO_2 , CH_2OR' ,~~
 ~~OR' , CH_2SR' , SR' , haloalkyl, $CH_2SO_2N(R')_2$, $SO_2N(R')_2$, $CH_2N(R')_2$, $N(R')_2$,~~
 ~~$NHCOR'$, CH_2NHCOR' , $CH_2PO(OR')_2$, $PO(OR')_2$ or two adjacent occurrences of~~
 ~~$Q-R^5$, taken together with the atoms to which they are bound, form an optionally~~
~~substituted saturated, partially unsaturated, or fully unsaturated 5-8 membered ring~~
~~having 0-3 heteroatoms selected from nitrogen, oxygen, or sulfur.~~

Applicants: Guy Benchley et al.
 Application No.: 10/809,946

9. (Original) The compound of claim 1, wherein Q-R⁵ substituents on Ar¹ are fluoro, iodo, chloro, bromo, COCH₃, CO₂CH₃, C₁₋₄alkyl, NH₂, CH₂NH₂, NHMe, CH₂NHMe, N(Me)₂, CH₂N(Me)₂, N(Et)₂, CH₂N(Et)₂, NH(phenyl), CO(C₁₋₄alkyl), CH₂CO(C₁₋₄alkyl), NHCO(C₁₋₄alkyl), CH₂NHCO(C₁₋₄alkyl), CN, CH₂CN, OH, C₁₋₄alkoxy, optionally substituted benzyloxy, optionally substituted phenyloxy, CF₃, SO₂NH₂, SO₂NHMe, optionally substituted SO₂(phenyl), SO₂(C₁₋₄alkyl), CONH₂, CH₂PO(OR')₂, or an optionally substituted group selected from a saturated, partially unsaturated, or fully unsaturated 5- or 6-membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

10. (Currently amended) The compound of claim 1, wherein R¹ and R² groups of formula I are each independently hydrogen, N(R)₂, SR, or OR, ~~or TR, or R¹ and R², taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-membered ring having 0-2 heteroatoms independently selected from N, O, or S.~~

11. (Currently amended) The compound of claim 1, wherein R¹ and R² groups are each independently hydrogen, OH, CH₃, CH₂CH₃, OCH₃, CH₂OH, CH₂OCH₃, CH₂NH₂, CH₂NHCH₃, NH₂, or CH₂NH₂, ~~or R¹ and R², taken together, form a fused optionally substituted pyrrolyl, pyrazolyl, or imidazolyl ring.~~

12. (Currently amended) The compound of claim 1, wherein R³ and R⁴ are each independently Z-R⁷ wherein Z is a bond or an optionally substituted C₁₋₄ [[C₀₋₄]] alkylidene chain wherein one methylene unit of Z is optionally replaced by O, NR, NRCO, NRCO₂, NRSO₂, CONR, C(O), C(O)O, and wherein R⁷ is selected from halogen, CN, N(R')₂, NHCOR', or R', ~~or wherein R³ and R⁴, taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5- or 6-membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.~~

Applicants: Guy Benchley et al
 Application No.: 10/809,946

13. (Currently amended) The compound of claim 1, wherein R^3 and R^4 are each independently hydrogen, CN, halogen, OH, SH, NH_2 , CO_2H , COH, $CONH_2$, SO_2NH_2 , NO_2 , or $(CH_2)_nNRR^7$, wherein R and R^7 , taken together with the nitrogen atom to which they are bound, form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur, ~~or R^3 and R^4 , taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5- or 6-membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and n is 0, 1, 2, 3, 4, or 5.~~

14. (Currently amended) The compound of claim 1, wherein one of R^3 or R^4 is hydrogen, and the other of R^3 or R^4 is ~~$(CH_2)_n$ halogen, $(CH_2)_n$ CN, $(CH_2)_nOR^7$, $(CH_2)_nNRR^7$, $(CH_2)_nC(O)R^7$, $(CH_2)_nC(O)R^7$ $(CH_2)_nCH_3$, or $(CH_2)_nC(O)NRR^7$, $(CH_2)_nSR^7$, wherein R^7 is hydrogen, $(CH_2)_mN(R')_2$, C_1 - C_4 alkyl, an optionally substituted 5- or 6-membered aryl or ~~alkyl~~, heteroaryl, wherein each of n and m is 0 or 1, or heteroalkyl group, or R and R^7 , taken together with the nitrogen atom to which they are bound form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur.~~

15. (Original) The compound of claim 14, wherein R^3 is hydrogen.

16. (Original) The compound of claim 14, wherein R^4 is hydrogen.


17. (Original) The compound of claim 1, wherein R^3 and R^4 , taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5- or 6-membered ring having 0-3

Applicants: Guy Benchley et al.
 Application No.: 10/809,946


heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is optionally substituted with 0, 1, 2, 3, 4, or 5 occurrences of Y-R⁸.

18. (Original) The compound of claim 17, wherein each occurrence of Y-R⁸ is independently methyl, ethyl, t-butyl, fluoro, chloro, bromo, oxo, CF₃, OMe, OEt, CN, SO₂Me, SO₂NH₂, NH₂, NHMe, N(Me)₂, SMe, SEt, OH, C(O)Me, NO₂, or CH₂OH.


19. (Original) The compound of claim 1, having one of formulas I-A-i, I-A-ii, I-B-i, I-B-ii, I-C-i, I-C-ii, I-D-i, or I-E-i:




I-A-i



I-A-ii




I-B-i




I-B-ii


Applicants: Guy Benchley et al.
 Application No.: 10/809,946




I-C-i



I-C-ii



I-D-i



I-E-i

wherein q is 0-5.

20-30. (Canceled)

31. (Currently amended) The compound of claim 19 [[25]], wherein R^3 is $Z-R^7$, wherein Z is a bond or is an optionally substituted C_{1-4} [[C₀₋₄]] alkylidene chain wherein one methylene unit of Z is optionally replaced by O, NR, NRCO, NRCO₂, NRSO₂, CONR, C(O), C(O)O, and wherein R^7 is halogen, CN, $N(R')_2$, NHCOR', or R' .

32. (Currently amended) The compound of claim 19 [[25]], wherein R^3 is $(CH_2)_n$ halogen, $(CH_2)_n$ CN, $(CH_2)_n$ OR⁷, $(CH_2)_n$ NRR⁷, $(CH_2)_n$ C(O)R⁷, $(CH_2)_n$ C(O)R⁷, $(CH_2)_n$ CH₃, or $(CH_2)_n$ C(O)NRR⁷, $(CH_2)_n$ SR⁷, wherein R^7 is hydrogen, $(CH_2)_m$ N(R')₂,

Applicants: Guy Benchley et al.
 Application No.: 10/809,946

C_1 - C_4 alkyl, an optionally substituted 5- or 6-membered aryl ~~or -alkyl~~, heteroaryl, wherein each of n and m is 0 or 1, or heteroalkyl group, or R and R^7 , taken together with the nitrogen atom to which they are bound form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur, n is 0 or 1, and m is 0 or 1.

33. (Currently amended) The compound of claim 19 [[25]], wherein Z is a bond or is an optionally substituted C_{1-4} [[C_{0-4}]] alkylidene chain wherein one methylene unit of Z is optionally replaced by O, NR, NRCO, NR CO_2 , NRSO $_2$, CONR, C(O), C(O)O, and wherein R^7 is selected from halogen, CN, $N(R')_2$, NHCOR', or R' .

34. (Currently amended) The compound of claim 19 [[25]], wherein R^4 is ~~$(CH_2)_n$ halogen, $(CH_2)_n$ CN, $(CH_2)_nOR^7$, $(CH_2)_nNRR^7$, $(CH_2)_nC(O)R^7$, $(CH_2)_nC(O)R^7$, $(CH_2)_nCH_3$, or $(CH_2)_nC(O)NRR^7$, $(CH_2)_nSR^7$~~ , wherein R^7 is hydrogen, $(CH_2)_mN(R')_2$, C_1 - C_4 alkyl, an optionally substituted 5- or 6-membered aryl ~~or -alkyl~~, heteroaryl, wherein each of n and m is 0 or 1, or heteroalkyl group, or R and R^7 , taken together with the nitrogen atom to which they are bound form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur, n is 0 or 1, and m is 0 or 1.

35. (Currently amended) The compound of claim 19 [[25]], wherein q is 0, 1, or 2, and each occurrence of $Y-R^8$ is independently methyl, ethyl, t-butyl, fluoro, chloro, bromo, oxo, CF_3 , OMe, OEt, CN, SO_2Me , SO_2NH_2 , NH_2 , NHMe, $N(Me)_2$, SMe, SEt, OH, C(O)Me, NO_2 , or CH_2OH .

36. (Currently amended) The compound of claim 19 [[25]], wherein compounds have one of formulas II-A-i, II-B-i, or II-C-i, and the compound variables are defined as:

Applicants: Guy Benchley et al.
 Application No.: 10/809,946

a) x is 0, 1, 2, or 3, and $Q-R^5$ is CH_2 halogen, halogen, CH_2CN , CN , CH_2CO_2R' , CO_2R' , CH_2COR' , COR' , R' , CH_2NO_2 , NO_2 , CH_2OR' , OR' , CH_2SR' , SR' , haloalkyl, $CH_2SO_2N(R')_2$, $SO_2N(R')_2$, $CH_2N(R')_2$, $N(R')_2$, $NHCOR'$, CH_2NHCOR' , $CH_2PO(OR')_2$, $PO(OR')_2$, or $Q-R^5$, taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-8-membered ring having 0-3 heteroatoms selected from nitrogen, oxygen, or sulfur;

b) R^1 and R^2 are each independently hydrogen, $N(R)_2$, SR , OR , or TR , or R^1 and R^2 , taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-membered ring having 0-2 heteroatoms independently selected from N, O, or S; and

c) R^3 is $(CH_2)_n$ halogen, $(CH_2)_nCN$, $(CH_2)_nOR^7$, $(CH_2)_nNRR^7$, $(CH_2)_nC(O)R^7$, $(CH_2)_nC(O)R^7$, $(CH_2)_nCH_3$, $(CH_2)_nC(O)NRR^7$, $(CH_2)_nSR^7$, wherein R^7 is $(CH_2)_mN(R')_2$, C_1 - C_4 alkyl, an optionally substituted 5- or 6-membered aryl, aralkyl, heteroaryl, or heteroaralkyl group, or R and R^7 , taken together with the nitrogen atom to which they are bound form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur, n is 0 or 1, and m is 0 or 1.

37. (Currently amended) The compound of claim 19 [[25]], wherein compounds have one of formulas II-A-ii, II-B-ii, or II-C-ii, and one or more of the compound variables are defined as:

a) x is 0, 1, 2, or 3, and $Q-R^5$ is CH_2 halogen, halogen, CH_2CN , CN , CH_2CO_2R' , CO_2R' , CH_2COR' , COR' , R' , CH_2NO_2 , NO_2 , CH_2OR' , OR' , CH_2SR' , SR' , haloalkyl, $CH_2SO_2N(R')_2$, $SO_2N(R')_2$, $CH_2N(R')_2$, $N(R')_2$, $NHCOR'$, CH_2NHCOR' , $CH_2PO(OR')_2$, $PO(OR')_2$, or $Q-R^5$, taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-8-membered ring having 0-3 heteroatoms selected from nitrogen, oxygen, or sulfur;

Applicants: Guy Benchley et al.
 Application No.: 10/809,946

b) R^1 and R^2 are each independently hydrogen, $N(R)_2$, SR, OR, or TR, or R^1 and R^2 , taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-membered ring having 0-2 heteroatoms independently selected from N, O, or S; and

c) R^4 is $(CH_2)_n$ halogen, $(CH_2)_n$ CN, $(CH_2)_nOR^7$, $(CH_2)_nNRR^7$, $(CH_2)_nC(O)R^7$, $(CH_2)_nC(O)R^7(CH_2)_nCH_3$, $(CH_2)_nC(O)NRR^7$, $(CH_2)_nSR^7$, wherein R^7 is $(CH_2)_mN(R')_2$, C_1 - C_4 alkyl, an optionally substituted 5- or 6-membered aryl, aralkyl, heteroaryl, or heteroaralkyl group, or R and R^7 , taken together with the nitrogen atom to which they are bound form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur, n is 0 or 1, and m is 0 or 1.

38. (Currently amended) The compound of claim 19 [[25]], wherein compounds have formula II-E-i, and one or more of the compound variables are defined as:


a) x is 0, 1, 2, or 3, and Q- R^5 is CH_2 halogen, halogen, CH_2 CN, CN, CH_2CO_2R' , CO_2R' , CH_2COR' , COR' , R' , CH_2NO_2 , NO_2 , CH_2OR' , OR' , CH_2SR' , SR' , haloalkyl, $CH_2SO_2N(R')_2$, $SO_2N(R')_2$, $CH_2N(R')_2$, $N(R')_2$, $NHCOR'$, CH_2NHCOR' , $CH_2PO(OR')_2$, $PO(OR')_2$, or Q- R^5 , taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-8-membered ring having 0-3 heteroatoms selected from nitrogen, oxygen, or sulfur;

b) R^1 and R^2 are each independently hydrogen, $N(R)_2$, SR, OR, or TR, or R^1 and R^2 , taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-membered ring having 0-2 heteroatoms independently selected from N, O, or S; and




c) q is 0, 1, or 2, and each occurrence of Y- R^8 is independently methyl, ethyl, t-butyl, fluoro, chloro, bromo, cxo, CF_3 , OMe, OEt, CN, SO_2Me , SO_2NH_2 , NH_2 , NHMe, $N(Me)_2$, SMe, SEt, OH, $C(O)Me$, NO_2 , or CH_2OH .

Applicants: Guy Benchley et al.
Application No.: 10/809,946




39. (Currently amended) The compound of claim 19 [[25]], The compound of claim 1, selected from:












Applicants: Guy Benchley et al.
Application No.: 10/809,946




Applicants: Guy Benchley et al.
Application No.: 10/809,946



Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-28****I-29****I-30****I-31****I-32****I-33****I-34****I-35****I-36**


Applicants: Guy Benchley et al.
Application No.: 10/809,946




I-37

I-38


I-39




I-40




I-41




I-42



I-43




I-44




I-45


Applicants: Guy Benchley et al.
Application No.: 10/809,946




I-46




I-47




I-48




I-49




I-50




I-51



I-52












I-53












I-54










Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-55****I-56****I-57****I-58****I-59****I-60****I-61****I-62****I-63**


Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-64****I-65****I-66****I-67****I-68****I-69**


Applicants: Guy Benchley et al.
Application No.: 10/809,946

I-70**I-71****I-72****I-73****I-74****I-75****I-76****I-77****I-78****I-79****I-80****I-81**


Applicants: Guy Benchley et al.
Application No.: 10/809,946




I-82




I-83




I-84




I-85




I-86




I-87



I-88






I-89












I-90


Applicants: Guy Benchley et al.
Application No.: 10/809,946




Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-100****I-101****I-102****I-103****I-104****I-105****I-106****I-107****I-108**


Applicants: Guy Benchley et al.
Application No.: 10/809,946




I-109




I-110




I-111




I-113




I-114




I-115



I-116












I-117












I-118










Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-119****I-120****I-121****I-122****I-123****I-124****I-125****I-126****I-127**

Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-128****I-129****I-130****I-131****I-132****I-133****I-134****I-135****I-136**


Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-137****I-138****I-139****I-140****I-141****I-142****I-143****I-144****I-145**


Applicants: Guy Benchley et al.
Application No.: 10/809,946




I-146




I-147




I-148




I-149




I-150



I-151












I-152












I-153










Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-154****I-155****I-156****I-157****I-158****I-159****I-160****I-161****I-162**










Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-163****I-164****I-165****I-166****I-167****I-168****I-169****I-170****I-171**










Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-172****I-173****I-174****I-175****I-176****I-177****I-178****I-179****I-180**



Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-181****I-182****I-183****I-184****I-185****I-186****I-187****I-188****I-189**


Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-190****I-191****I-192****I-193****I-194****I-195****I-196****I-197****I-198**


Applicants: Guy Benchley et al.
Application No.: 10/809,946




Applicants: Guy Benchley et al.
Application No.: 10/809,946



I-207




I-208




I-209




I-210




I-211




I-212



I-213











I-214




I-215


Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-216****I-217****I-218****I-219****I-220****I-221****I-222****I-223****I-224**


Applicants: Guy Benchley et al.
Application No.: 10/809,946




I-225




I-226




I-227




I-228




I-229




I-230



I-231




I-232




I-233


Applicants: Guy Benchley et al.
Application No.: 10/809,946




I-234




I-235




I-236




I-237




I-238



I-239




I-240




I-241


Applicants: Guy Benchley et al.
Application No.: 10/809,946




I-242




I-243




I-244




I-245




I-246




I-247



I-248












I-249










I-250









Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-251****I-252****I-253****I-254****I-255****I-256****I-257****I-258****I-259**


Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-260****I-261****I-262****I-263****I-264****I-265****I-266**


Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-267****I-268****I-269****I-270****I-271****I-272****I-273****I-274**


Applicants: Guy Benchley et al.
Application No.: 10/809,946




I-275




I-276




I-277




I-278




I-279




I-280



I-281




I-282




I-283


Applicants: Guy Benchley et al.
 Application No.: 10/809,946



I-284



I-285



I-286

40. (Original) A composition comprising a compound of claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

41. (Canceled)

42. (Original) The composition of claim 40, additionally comprising a therapeutic agent selected from an anti-inflammatory agent, an anti-proliferative agent, an immunomodulatory or immunosuppressive agent, or an agent for treating immunodeficiency disorders.

43. (Currently amended) A method of inhibiting SYK or ZAP-70 kinase activity in:

(a) a patient; or

(b) a biological sample;

which method comprises administering to said patient, or contacting said biological sample with:

a) a composition of claim 40; or

b) a compound of claim 1.

Applicants: Guy Benchley et al.
 Application No.: 10/809,946

44. (Currently amended) A method of treating or lessening the severity of treatment or lessening the severity of lepromatous leprosy ~~an immunodeficiency disorder~~, atopic dermatitis, contact dermatitis, seborrhectic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia, areata, vernal conjunctivitis, eosinophilia fasciitis ~~inflammatory disease~~, Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, pancreatitis, Crohn's disease, ulcerative colitis, migraine, rhinitis, ~~allergic disease~~, multiple sclerosis, lupus erythematosus, rheumatoid arthritis, type I diabetes, psoriasis, seronegative spondyloarthropathis, Behcet's disease, Sjogren's syndrome, systemic sclerosis, Hashimoto's thyroiditis, myasthenia gravis, nephrotic syndrome, idiopathic thrombocytopenia purpura, hyper IgE syndrome ~~autoimmune disease~~, leukemia, lymphoma, Sezary syndrome, restenosis following angioplasty, atherosclerosis ~~proliferative disorder~~, allograft rejection, graft versus host disease ~~immunologically mediated disease~~, or asthma, ~~respiratory disorder~~, comprising the step of administering to said patient:

- a) a composition of claim 40; or
- b) a compound of claim 1.

45. (Currently amended) The method according to claim 41, comprising the additional step of administering to said patient an additional therapeutic agent selected from an anti-inflammatory agent, an anti-proliferative agent, an immunomodulatory or immunosuppressive agent, or an agent for treating immunodeficiency disorders, wherein: said additional therapeutic agent is appropriate for the disease being treated[[:]] and ~~said additional therapeutic agent~~ is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.

Applicants: Guy Benchley et al.
Application No.: 10/809,946

46. (Currently amended) The method according to claim 44, wherein the disease is multiple sclerosis, lupus erythematosus, rheumatoid arthritis, type I diabetes, psoriasis, seronegative spondyloarthropathis, Behcet's disease, Sjogren's syndrome, systemic sclerosis, Hashimoto's thyroiditis, myasthenia gravis, nephrotic syndrome, idiopathic thrombocytopenia purpura, or hyper IgE syndrome ~~an immune disorder~~.

47. (Original) The method according to claim 44, wherein the disease is asthma.